These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34445019)

  • 21. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
    Tan W; Sun J; Zhou L; Li Y; Wu X
    J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.
    Ringe JD; Dorst A; Farahmand P
    Arzneimittelforschung; 2010; 60(5):267-72. PubMed ID: 20533764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phytate levels and bone parameters: a retrospective pilot clinical trial.
    Lopez-Gonzalez AA; Grases F; Perello J; Tur F; Costa-Bauza A; Monroy N; Mari B; Vicente-Herrero T
    Front Biosci (Elite Ed); 2010 Jun; 2(3):1093-8. PubMed ID: 20515779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
    Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
    Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urinary phytate (Myo-inositol hexaphosphate) in healthy school children and risk of nephrolithiasis.
    Grases F; Saez-Torres C; Rodriguez A; Costa-Bauza A; Rodrigo D; Frontera G; Berga F; Fakier S
    J Ren Nutr; 2014 Jul; 24(4):219-23. PubMed ID: 24788309
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
    Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Clin Rheumatol; 2004 Oct; 23(5):383-9. PubMed ID: 15278749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phytate Decreases Formation of Advanced Glycation End-Products in Patients with Type II Diabetes: Randomized Crossover Trial.
    Sanchis P; Rivera R; Berga F; Fortuny R; Adrover M; Costa-Bauza A; Grases F; Masmiquel L
    Sci Rep; 2018 Jun; 8(1):9619. PubMed ID: 29941991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion.
    Córdoba A; Hierro-Oliva M; Pacha-Olivenza MÁ; Fernández-Calderón MC; Perelló J; Isern B; González-Martín ML; Monjo M; Ramis JM
    ACS Appl Mater Interfaces; 2016 May; 8(18):11326-35. PubMed ID: 27088315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A; Snelder AA; Mulder H
    Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
    Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
    Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
    Takata S; Abbaspour A; Yonezu H; Yasui N
    J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V; Arce-Salinas CA; Espinosa-Ortega F
    J Clin Densitom; 2014; 17(4):484-9. PubMed ID: 24613450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.